Moderna, the biotechnology company known for its COVID-19 vaccine, has revised its 2025 sales forecast downward due to a combination of factors, including sluggish adoption of its RSV shot and declining demand for COVID-19 vaccines. The company is implementing cost-cutting measures and focusing on new product development to navigate these challenges.
Moderna lowered its 2025 sales forecast by $1 billion on Monday, citing sluggish adoption of its respiratory syncytial virus ( RSV ) shot and waning demand for COVID-19 vaccines. The company's revenue projections for 2025 now stand at $1.5 billion to $2.5 billion, primarily concentrated in the second half of the year. This revised forecast falls short of the previous estimate of $2.5 billion to $3.5 billion and the market expectation of $2.95 billion, according to data from LSEG.
Moderna attributes the shortfall to a combination of factors, including the diminishing need for COVID-19 vaccines as the pandemic's intensity subsides and the slower-than-anticipated uptake of its RSV shot, which represents its second approved product. To mitigate these challenges, Moderna plans to reduce 2025 cash costs by $1 billion, with an additional $500 million in cost reductions targeted for 2026. The company anticipates ending 2025 with cash and investments of approximately $6 billion.Despite the near-term headwinds, Moderna remains optimistic about its long-term prospects, pinning its hopes on new product launches to drive future growth. The company has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of its combination vaccine designed to protect against both COVID-19 and influenza. The FDA is scheduled to make a decision on this application by May. Moderna also expects to release data from a trial of its seasonal flu shot this year, contingent upon sufficient case accrual during the first season. If the required number of cases is not reached, the study will proceed into a second season. Moreover, an independent group has informed Moderna that a late-stage trial of its cytomegalovirus (CMV) vaccine has not yet met the criteria for early efficacy. However, the group has recommended that the study continue, with Moderna now anticipating data from this trial this year. The company is scheduled to announce its fourth-quarter results on February 14. Shares of Moderna declined to $34.59 before the opening bell on Monday, marking a significant drop of 58% in value last year
Moderna COVID-19 RSV Vaccines Sales Forecast Biotechnology Healthcare Pharmaceuticals
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tesla is recalling almost 700,000 vehicles due to a tire pressure monitoring system issueThe recall includes certain 2024 Cybertruck, 2017-2025 Model 3, and 2020-2025 Model Y vehicles.
Read more »
14 lessons from 2025 to remember in 2025: BofA14 lessons from 2025 to remember in 2025: BofA
Read more »
My Hero Academia: Vigilantes Anime Gets April 2025 Premiere & Final Season Set for Fall 2025My Hero Academia, one of the most popular anime franchises in recent years, is getting both a spin-off anime and its final season. The spin-off, My Hero Academia: Vigilantes, will premiere in April 2025. The final season of the main series is set to air in autumn 2025
Read more »
Frankencar 2025: The best of the Motor Authority Best Car To Buy 2025 finalistsTaking the best bits from our award finalists this year, this latest creation is electric with power, style, and three rows of seats.
Read more »
AIMA Tech Unveils 2025 eBike Lineup at CES 2025AIMA Tech, a global leader in sustainable mobility, unveils its groundbreaking 2025 eBike lineup at CES 2025. The new lineup features eight new models and three upgraded designs, each tailored to meet diverse rider needs.
Read more »
Moderna Stock Plummets as Revenue Projections Fall ShortModerna Inc. shares experienced a significant drop on Monday following the biotech firm's projections of a substantial decline in 2025 revenues, falling below Wall Street expectations. The company, renowned for its COVID-19 vaccine Spikevax, anticipates revenue ranging from $1.5 billion to $2.5 billion in 2025, a stark contrast to its peak pandemic performance of $19 billion. Moderna's revenue and stock price have been steadily declining since global demand for COVID-19 vaccines waned. While its newer RSV vaccine has underperformed, Moderna is exploring cost-cutting measures to navigate this financial transition.
Read more »